@article{c21b14522d5d40e0b696b42748c04121,
title = "When in the treatment continuum to use PARP inhibition in ovarian cancer",
keywords = "Antineoplastic Combined Chemotherapy Protocols/adverse effects, Biomarkers, Tumor, Carcinoma, Ovarian Epithelial/drug therapy, Drug Administration Schedule, Drugs, Investigational/administration \& dosage, Female, Humans, Ovarian Neoplasms/drug therapy, Poly(ADP-ribose) Polymerase Inhibitors/administration \& dosage, Practice Patterns, Physicians', Recurrence, Remission Induction, Salvage Therapy, Treatment Outcome",
author = "Mirza, \{Mansoor Raza\}",
year = "2021",
month = feb,
language = "English",
volume = "19",
pages = "84--86",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "2",
}